Innovación, terapia y desarrollo farmacéutico en oftalmología
INNOFTAL
![Foto de Innovación, terapia y desarrollo farmacéutico en oftalmología](/img/grupo.png)
![Foto de Hospital de Gran Canaria Dr. Negrin](/img/noimage_org.png)
Hospital de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, EspañaPublications en collaboration avec des chercheurs de Hospital de Gran Canaria Dr. Negrin (8)
2024
-
Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI©
Ophthalmology and Therapy, Vol. 13, Núm. 6, pp. 1669-1682
2023
-
Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients
Seminars in Arthritis and Rheumatism, Vol. 58
-
Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis (Ophthalmology and Therapy, (2023), 12, 2, (1045-1055), 10.1007/s40123-023-00654-8)
Ophthalmology and Therapy
-
SER recommendations for the treatment of uveitis
Reumatologia Clinica, Vol. 19, Núm. 9, pp. 465-477
-
Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis
Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 1045-1055
2022
-
Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study
BMJ open, Vol. 12, Núm. 3, pp. e051378
2019
-
Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases
Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089
2017
-
Development of an activity disease score in patients with uveitis (UVEDAI)
Rheumatology International, Vol. 37, Núm. 4, pp. 647-656